TransMedics Group (NASDAQ:TMDX) Stock Price Down 4% - Here's What Happened

Key Points

• TransMedics Group's stock price fell 4% to $107.04, with trading volume down 89% from its average.
• Despite the recent decline, analysts maintain a Moderate Buy consensus rating for TMDX, with price targets ranging from $123.00 to $150.00.
• In its latest earnings report, TransMedics Group posted an EPS of $0.92, surpassing estimates and marking a 37.7% year-over-year revenue increase.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s share price was down 4% on Wednesday . The company traded as low as $107.70 and last traded at $107.04. Approximately 142,955 shares changed hands during trading, a decline of 89% from the average daily volume of 1,301,407 shares. The stock had previously closed at $111.55.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TMDX shares. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Morgan Stanley upped their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Oppenheimer upped their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Finally, Canaccord Genuity Group upped their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Stock Performance

The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The company's 50-day simple moving average is $119.57 and its 200-day simple moving average is $103.65. The stock has a market capitalization of $3.68 billion, a price-to-earnings ratio of 56.07 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. During the same period in the prior year, the company posted $0.35 EPS. The company's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently modified their holdings of the company. Thrivent Financial for Lutherans increased its position in shares of TransMedics Group by 0.9% during the second quarter. Thrivent Financial for Lutherans now owns 24,879 shares of the company's stock worth $3,334,000 after buying an additional 227 shares during the period. State of Wyoming acquired a new stake in shares of TransMedics Group during the second quarter worth $76,000. Caxton Associates LLP acquired a new stake in shares of TransMedics Group during the second quarter worth $242,000. Public Sector Pension Investment Board increased its position in shares of TransMedics Group by 8.3% during the second quarter. Public Sector Pension Investment Board now owns 115,335 shares of the company's stock worth $15,456,000 after buying an additional 8,855 shares during the period. Finally, Evergreen Capital Management LLC acquired a new stake in shares of TransMedics Group during the second quarter worth $303,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.